Invitae Immunologic, Metabolic, Newborn Screening Confirmation Panels
Invitae announced it has added 80 new panels and updated 24 panels for the diagnosis of inherited immunologic and metabolic disorders, as well as panels that confirm diagnoses suggested by newborn screening. Some of these offerings include new and updated lysosomal storage disorder panels covering 52 genes; an updated, 90-gene newborn screening confirmation panel; a new panel of 133 genes for diagnosing treatable neurometabolic disorders; a new panel of more than 200 genes linked to primary immunodeficiencies; and a new 46-gene panel for associated monogenic forms of inflammatory bowel disease. Additionally, the firm includes deletion/duplication analysis at no extra charge in an effort to identify between 5 percent and 10 percent of pathogenic variants that are difficult to gauge with next-generation sequencing.
Biogazelle mRNA Sequencing
Biogazelle has launched its mRNA sequencing service for human plasma and other bodily fluids. The company uses massively parallel sequencing to quantify and characterize mRNA molecules in low volumes of plasma and can detect between 6,000 and 8,000 genes, it said. This type of analysis provides an order of magnitude more biomarkers than microRNA sequencing, and since it is a liquid biopsy-based technology it allows for serial follow-up of patients to monitor them for disease, the company added.
For more new products and services, please visit the New Products page on our website.